Get the Daily Brief
Latest Biotech News
IPO surge for Parabilis and record-setting public-market appetite
Parabilis Medicines—formerly FogPharma—has priced an upsized $670 million biotech IPO, setting a new record for venture-backed drug companies going public. The offering totals 33.3 million shares...
Big Pharma expands into molecular glue with Orionis deal
Novartis has signed a second molecular-glue partnership with Orionis Biosciences, adding $40 million upfront and up to $1.4 billion in milestone-based consideration. The deal focuses on Orionis’s...
Ultrasound-based gene delivery gains clinical funding momentum
SonoThera has raised $125 million to advance its ultrasound-based, non-viral gene therapy platform into the clinic. The funding round is led by Vida Ventures, with participation from large pharma...
GSK acquires Nuvalent to build a lung cancer franchise
GSK has agreed to buy Nuvalent for roughly $10.6 billion in cash, a move designed to add two late-stage lung cancer programs to its pipeline. The deal brings ROS1 inhibitor zidesamtinib and ALK...
Illumina demand resilience and multiomics positioning
JP Morgan upgraded Illumina to Overweight from Neutral, arguing the sequencing platform’s customer retention and spend outlook have become clearer. The bank cited survey work with 62 Illumina...
Diagnostics access expands for RNA-based colorectal screening via Medicare
Geneoscopy’s stool-based RNA colorectal screening test, ColoSense, has received coverage under a National Coverage Determination from the U.S. Centers for Medicare and Medicaid Services. The...
Regulatory signal for ultrasound-aided genetic delivery program funding
A pair of separate launches highlight rising interest in modality-first gene delivery and platform integration. In one case, SonoThera’s funding accelerates its pathway into clinical evaluation...
Incyte expands hematology with Vega acquisition for von Willebrand disease
Incyte has agreed to acquire Vega Therapeutics for up to $2 billion, aiming to strengthen its hematology pipeline with VGA039, a Phase III von Willebrand disease (VWD) candidate. Vega is a Star...
Oncolytic virus gets Japan approval for esophageal cancer
Japan has granted marketing approval to Oncolys Biopharma’s oncolytic adenovirus Telomelysin (suratadenoturev, OBP-301) for treating esophageal cancer patients who are not eligible for curative...
Medicare coverage expands RNA-based colorectal screening
Geneoscopy said the U.S. Centers for Medicare and Medicaid Services expanded national coverage for colorectal cancer screening tests to include its ColoSense stool-based RNA assay. The update adds...
Illumina gets analyst confidence boost as customer spending outlook improves
JP Morgan upgraded Illumina to Overweight and set a $185 price target after surveying instrument and clinical customers about the sequencing competitive landscape. The analyst said Illumina’s...
10x Genomics buys Proteintech Genomics to deepen proteomics
10x Genomics said it acquired Proteintech Genomics to expand proteomics capabilities and strengthen multiomics workflows. The companies did not disclose the acquisition price. The move is aimed at...
Geneoscopy and Labcorp coverage tie-in underscores diagnostics reimbursement momentum
Geneoscopy said the updated CMS coverage determination for colorectal cancer screening provides a pathway that supports future RNA-based stool assays. The company positioned the decision as a...
10x and proteomics market integration continues to accelerate
10x Genomics said it will extend proteomics capabilities through its acquisition of Proteintech Genomics. The company characterized the purchase as strengthening its roadmap for integrated...
Sanofi ends late-stage nerve disease program after efficacy concern
Sanofi said it will stop a Phase 3 trial of riliprubart in a rare neurological disorder after an independent committee determined the study was unlikely to show sufficient efficacy. The decision...
Infectious disease: early clinical data for dual Lassa–rabies vaccine
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported interim results from a Phase 1 trial of a dual vaccine targeting Lassa...
Dealmaking: J&J acquires Firefly Bio to bring degrader-antibody conjugates platform in-house
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, gaining a platform for degrader antibody conjugates and strengthening its oncology pipeline technology base. J&J said the...
Dealmaking: GSK’s $10.6B Nuvalent purchase targets near-commercial lung cancer drugs under FDA review
GSK agreed to acquire Nuvalent for $10.6 billion in cash, a deal designed to add two near-commercial lung cancer therapies that are under FDA review. The acquisition includes ROS1 and ALK targeted...
Biotech financing: Parabilis upsized $670M IPO to back cancer pipeline
Parabilis Medicines priced an upsized IPO intended to raise $670 million, setting the company up to fund a multi-asset cancer pipeline. The clinical-stage firm offered 33.3 million shares at $20...
Degrader-antibody conjugates move from platforms to late-stage targets
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, stepping deeper into degrader-antibody conjugates (DACs) with a KRAS-focused technology and a new linker approach aimed at more...